SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class

BACKGROUND: For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Schernthaner, Guntram, Drexel, Heinz, Moshkovich, Evgeny, Zilaitiene, Birute, Martinka, Emil, Czupryniak, Leszek, Várkonyi, Tamás, Janež, Andrej, Ducena, Kristine, Lalić, Katarina, Tankova, Tsvetalina, Prázný, Martin, Smirčić Duvnjak, Lea, Sukhareva, Olga, Sourij, Harald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580491/
https://www.ncbi.nlm.nih.gov/pubmed/31208401
http://dx.doi.org/10.1186/s12902-019-0387-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580491/
https://www.ncbi.nlm.nih.gov/pubmed/31208401
http://dx.doi.org/10.1186/s12902-019-0387-y

Ejemplares similares